IDEXX Laboratories (IDXX) is a publicly traded Healthcare sector company. As of May 20, 2026, IDXX trades at $551.48 with a market cap of $43.05B and a P/E ratio of 40.37. IDXX moved +1.27% today. Year to date, IDXX is -18.86%; over the trailing twelve months it is +7.04%. Its 52-week range spans $356.14 to $769.98. Analyst consensus is buy with an average price target of $693.17. Rallies surfaces IDXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes IDXX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $551.48 |
| Market Cap | $43.05B |
| P/E Ratio | 40.37 |
| EPS | $13.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $769.98 |
| 52-Week Low | $356.14 |
| Volume | 435.42K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.45B |
| Net Income | $1.10B |
| Gross Margin | 62.05% |
7 analysts cover IDXX: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $693.17.